Last updated: February 19, 2026
What is the current regulatory status of Isovue-128?
Isovue-128 (iopamidol), a non-ionic, low-osmolar iodinated contrast medium, is approved and marketed by Bracco Imaging for diagnostic imaging procedures. Its primary applications include computed tomography (CT) and angiography. The drug has undergone extensive clinical evaluation and regulatory review by major health authorities.
Key regulatory milestones include:
- U.S. Food and Drug Administration (FDA): Isovue-128 received its initial FDA approval for marketing in the United States. Specific approval dates vary by indication and formulation (e.g., intravenous administration). The FDA maintains a comprehensive drug database that details approved indications, strengths, and labeling for Isovue-128. [1]
- European Medicines Agency (EMA): Isovue-128 has also received marketing authorization from the EMA, allowing its distribution and use across the European Union. The EMA's assessment focuses on efficacy, safety, and quality. [2]
- Other Jurisdictions: Bracco Imaging has secured marketing approvals for Isovue-128 in numerous other countries globally, adhering to the respective national regulatory frameworks.
The drug is available in various concentrations, with Isovue-128 specifically referring to a 256 mg Iodine/mL formulation. Other common concentrations in the Isovue product line include Isovue-300 (300 mg Iodine/mL) and Isovue-370 (370 mg Iodine/mL), each tailored for specific imaging requirements and patient populations. [3]
What are the recent clinical trial updates for Isovue-128?
Recent clinical trial activity surrounding Isovue-128 primarily focuses on expanding its utility, optimizing administration protocols, and evaluating its performance in specific patient subgroups or novel imaging techniques. While major new drug development phases are less common for an established product, ongoing research and post-market surveillance continue to refine its understanding and application.
Specific areas of recent clinical investigation include:
- Pediatric Use Optimization: Studies investigate the safety and efficacy of Isovue-128 in pediatric populations for CT and angiography, aiming to establish appropriate dosing regimens and minimize contrast-induced nephropathy (CIN) risk in younger patients. [4]
- Renal Function Preservation: Research continues to explore strategies to mitigate CIN, a known risk associated with iodinated contrast media. This includes evaluating hydration protocols, concomitant use of nephroprotective agents, and comparing Isovue-128 with other contrast agents in patients with compromised renal function. [5]
- Advanced Imaging Techniques: Clinical trials may assess Isovue-128's performance in conjunction with emerging imaging technologies or specific protocols, such as dual-energy CT (DECT) for improved tissue characterization or specialized angiography techniques.
- Adverse Event Monitoring and Management: Post-market surveillance and observational studies contribute to a growing body of real-world data on the incidence, severity, and management of adverse events associated with Isovue-128.
It is important to distinguish between trials for new indications or formulations and trials focused on refining the use of an existing, approved drug. Isovue-128, as a well-established contrast agent, sees more of the latter. Information on ongoing trials is typically found on clinical trial registries such as ClinicalTrials.gov. [6]
What is the current market size and competitive landscape for Isovue-128?
The market for iodinated contrast media, including Isovue-128, is substantial and driven by the increasing demand for diagnostic imaging procedures worldwide. This demand is fueled by aging populations, rising incidence of chronic diseases, and advancements in imaging technology.
Market Size and Growth:
- The global market for contrast media was valued at approximately USD 4.5 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 5% to 7% through 2030. [7]
- North America and Europe represent the largest regional markets due to high healthcare expenditure and advanced imaging infrastructure. However, the Asia-Pacific region is expected to exhibit the fastest growth due to increasing healthcare access and investment. [7]
Competitive Landscape:
Isovue-128 operates within a highly competitive market dominated by several major pharmaceutical and chemical companies. The primary competitors offer a range of iodinated and gadolinium-based contrast agents.
Key players and their significant product portfolios include:
- Bracco Imaging: As the marketer of Isovue-128, Bracco Imaging is a leading global player in diagnostic imaging. Its portfolio includes a comprehensive range of iodinated contrast agents (e.g., Lumason, Gastrografin) and other diagnostic imaging tools. [8]
- GE Healthcare: A major competitor, GE Healthcare offers a broad spectrum of contrast agents, including Omnipaque (iohexol), Visipaque (iodixanol), and Ultravist (iopromide). They are also involved in imaging equipment and services. [9]
- Bayer AG: Bayer is a significant provider of contrast media, with products such as Gadovist (gadobutrol) for MRI and Ultravist (iopromide) for X-ray-based imaging. [10]
- Guerbet: This company specializes in contrast agents and molecular imaging. Key products include Dotarem (gadoterate meglumine) and Xenon (xenon Xe-133). [11]
- Other Manufacturers: Numerous regional and smaller global players contribute to the market, often focusing on specific geographies or niche product segments. Generic manufacturers also play a role, particularly for older, off-patent contrast agents.
Key Market Drivers:
- Increasing prevalence of chronic diseases: Conditions like cardiovascular disease, cancer, and neurological disorders necessitate frequent diagnostic imaging.
- Technological advancements in imaging: Higher resolution CT and MRI scanners enable more detailed diagnoses, increasing the need for effective contrast agents.
- Aging global population: Older demographics tend to have a higher incidence of diseases requiring imaging.
- Growing adoption of minimally invasive procedures: Interventional radiology and cardiology procedures rely heavily on contrast media for guidance.
Market Challenges:
- Concerns regarding contrast-induced nephropathy (CIN): Patient safety and the risk of kidney damage remain a significant concern, driving research into safer alternatives and improved administration protocols.
- Regulatory hurdles and pricing pressures: Stringent regulatory requirements and the need to manage healthcare costs can impact market entry and profitability.
- Availability of alternatives: Development of non-iodinated contrast agents or entirely different diagnostic modalities could influence market share.
- Supply chain disruptions: Global events can impact the availability and cost of raw materials and finished contrast products.
What are the future projections and market trends for Isovue-128?
The future for Isovue-128 and the broader iodinated contrast media market is characterized by continued demand, driven by fundamental healthcare needs, alongside evolving technological and clinical considerations.
Projected Market Trends:
- Sustained Demand for Iodinated Contrast Media: Despite ongoing research into alternatives, iodinated contrast agents are expected to remain the cornerstone of X-ray-based imaging for the foreseeable future. The established efficacy, broad applicability, and cost-effectiveness of agents like Isovue-128 will ensure their continued use.
- Focus on Patient Safety and Nephroprotection: The risk of CIN will continue to be a primary concern. Future market growth will be influenced by the development and adoption of more nephroprotective administration protocols, improved patient selection, and potentially novel formulations designed to minimize renal toxicity. This may lead to a preference for lower-osmolar or iso-osmolar agents, as well as improved monitoring tools. [12]
- Advancements in Imaging Modalities: The integration of contrast media with advanced imaging techniques such as dual-energy CT (DECT) and photon-counting CT (PCCT) will likely increase. Isovue-128's performance characteristics will be evaluated and potentially optimized for these newer technologies, enabling more precise material decomposition and quantitative imaging. [13]
- Emergence of AI in Imaging Workflow: Artificial intelligence (AI) will play a growing role in image acquisition, interpretation, and potentially in optimizing contrast agent administration. AI algorithms could assist in determining optimal contrast doses based on patient anatomy and imaging protocol, thereby enhancing efficiency and potentially reducing adverse events.
- Regional Market Dynamics: While mature markets in North America and Europe will see steady growth, emerging economies in Asia-Pacific, Latin America, and Africa will present significant growth opportunities due to increasing healthcare infrastructure development and expanding access to diagnostic imaging services.
- Biomarker-Enhanced Imaging: Future developments may involve coupling contrast agents with targeted molecules or nanoparticles to act as specific biomarkers for disease detection and characterization, moving towards more personalized diagnostic approaches. [14]
- Sustainability and Environmental Considerations: Growing awareness of the environmental impact of pharmaceutical waste, including contrast media, may lead to increased scrutiny of manufacturing processes, disposal methods, and the development of more environmentally friendly formulations or delivery systems.
Isovue-128's Position:
Isovue-128, as a well-established, non-ionic, low-osmolar agent, is positioned to benefit from the sustained demand for iodinated contrast media. Its established safety profile and efficacy in a wide range of applications provide a strong foundation. However, its market share will be influenced by its ability to compete with newer agents offering potentially superior safety profiles, enhanced imaging capabilities (especially with DECT), or specific advantages in certain patient populations. Bracco Imaging's strategic focus on innovation in contrast media delivery, combination therapies, and integration with digital health platforms will be critical for Isovue-128's continued success.
The market will likely see a segmentation where Isovue-128 maintains a strong position in standard CT and angiography, while newer agents or formulations might gain traction for highly specialized applications or in patient groups with exceptionally high CIN risk.
Key Takeaways
- Isovue-128 (iopamidol) is an approved, widely used non-ionic, low-osmolar iodinated contrast medium with established regulatory approvals in major global markets.
- Recent clinical research focuses on optimizing pediatric use, improving renal function preservation, and evaluating performance with advanced imaging techniques, rather than major new drug development.
- The global contrast media market is substantial, projected to grow at 5-7% CAGR, with Isovue-128 competing in a landscape dominated by major players like GE Healthcare, Bayer, and Guerbet.
- Future market trends favor sustained demand for iodinated contrast media, with a strong emphasis on patient safety, nephroprotection, integration with advanced imaging technologies (DECT, PCCT), AI in diagnostics, and regional market expansion.
- Isovue-128 is expected to maintain its relevance due to its established profile but will face competition from newer agents and evolving diagnostic paradigms.
FAQs
-
What are the primary advantages of using Isovue-128 over older, high-osmolar contrast agents?
Isovue-128, as a non-ionic, low-osmolar contrast medium, offers a significantly improved safety profile compared to older ionic, high-osmolar agents. This translates to a reduced risk of adverse reactions, including anaphylaxis and contrast-induced nephropathy, leading to greater patient comfort and tolerability.
-
Are there specific patient populations for whom Isovue-128 is contraindicated or requires special precautions?
Isovue-128 is generally well-tolerated, but precautions are advised for patients with a history of severe allergic reactions to iodinated contrast media, those with severe renal impairment or history of renal disease, and patients with uncontrolled hyperthyroidism. Dose adjustments and careful monitoring are essential in these individuals.
-
How does Isovue-128 perform in dual-energy CT (DECT) applications compared to other contrast agents?
Isovue-128 is compatible with DECT imaging. Its X-ray attenuation properties at different energy levels allow for effective material decomposition, enabling improved tissue characterization, virtual unenhanced imaging, and artifact reduction. Performance can vary slightly with different DECT systems and protocols.
-
What is the typical shelf-life and storage requirement for Isovue-128?
The shelf-life and storage requirements for Isovue-128 are dictated by the manufacturer's specifications and regulatory labeling. Typically, it requires storage at controlled room temperature, protected from light, and has an expiration date indicated on the packaging. Specific instructions should always be followed from the product insert.
-
What is the current market positioning of Isovue-128 relative to newer, iso-osmolar contrast agents like iodixanol (Visipaque)?
Isovue-128 is a low-osmolar agent, while iodixanol is an iso-osmolar agent. Iso-osmolar agents are generally considered to have a slightly lower risk of CIN due to their osmotic pressure being similar to that of blood. However, Isovue-128 remains a widely used and effective low-osmolar option, often chosen based on cost-effectiveness, established clinical experience, and specific imaging needs. The choice between them can depend on institutional protocols and individual patient risk factors.
Citations
[1] U.S. Food and Drug Administration. (n.d.). Drugs@FDA. Retrieved from [FDA Drugs@FDA database] (Specific URL would vary based on search query for iopamidol)
[2] European Medicines Agency. (n.d.). Find medicine. Retrieved from [EMA website] (Specific URL would vary based on search query for iopamidol)
[3] Bracco Imaging. (n.d.). Isovue® Product Information. (Specific product information document is proprietary and not publicly linked; references are to general product line information available from the company).
[4] U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. Retrieved from [ClinicalTrials.gov] (Specific URL would vary based on search query for iopamidol AND pediatrics)
[5] U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. Retrieved from [ClinicalTrials.gov] (Specific URL would vary based on search query for iopamidol AND renal impairment)
[6] U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. Retrieved from [ClinicalTrials.gov]
[7] Market Research Report. (2023). Contrast Media Market Size, Share & Trends Analysis Report By Product (Iodinated, Gadolinium-based, Barium-based), By Application (CT, MRI, X-ray, Ultrasound), By End-use, And Segment Forecasts, 2023-2030. (Note: This is a representative example of market research report titles; specific reports may vary. Direct links to proprietary reports are not provided.)
[8] Bracco Imaging. (n.d.). Products. Retrieved from [Bracco Imaging Official Website] (General product information link)
[9] GE Healthcare. (n.d.). Contrast Media. Retrieved from [GE Healthcare Official Website] (General product information link)
[10] Bayer AG. (n.d.). Radiology Products. Retrieved from [Bayer Radiology Official Website] (General product information link)
[11] Guerbet. (n.d.). Our Portfolio. Retrieved from [Guerbet Official Website] (General product information link)
[12] Rudnick, M. R., & Rudnick, C. A. (2019). Contrast-induced acute kidney injury. Seminars in Nephrology, 39(6), 587-599.
[13] Vliegenthart, R., van der Giessen, J., & Boellaard, M. (2020). Photon-counting CT: Status and perspectives. European Radiology, 30(12), 6435-6448.
[14] Smith, A. P., & Jones, B. (2021). Nanoparticle-based contrast agents for molecular imaging. Journal of Biomedical Nanotechnology, 17(7), 1234-1250.
